End-of-day quote
Budapest S.E.
18:00:00 2024-07-04 EDT
|
5-day change
|
1st Jan Change
|
14.55
HUF
|
+0.34%
|
|
+1.75%
|
+2.46%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,780
|
2,185
|
2,207
|
2,133
|
2,103
|
Enterprise Value (EV)
1 |
1,047
|
-601.6
|
-2,143
|
-2,189
|
-2,033
|
P/E ratio
|
-52.6
x
|
66.4
x
|
151
x
|
16.3
x
|
12.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2,374
x
|
4,856
x
|
4,904
x
|
4,740
x
|
4,674
x
|
EV / Revenue
|
1,396
x
|
-1,337
x
|
-4,762
x
|
-4,864
x
|
-4,517
x
|
EV / EBITDA
|
-110
x
|
32.9
x
|
171
x
|
139
x
|
97.1
x
|
EV / FCF
|
-
|
-2,341,480
x
|
182,131,746
x
|
12,749,222
x
|
1,709,076
x
|
FCF Yield
|
-
|
-0%
|
0%
|
0%
|
0%
|
Price to Book
|
0.8
x
|
0.61
x
|
0.43
x
|
0.4
x
|
0.38
x
|
Nbr of stocks (in thousands)
|
37,166
|
91,431
|
148,111
|
148,111
|
148,111
|
Reference price
2 |
47.90
|
23.90
|
14.90
|
14.40
|
14.20
|
Announcement Date
|
3/19/21
|
3/19/21
|
4/19/22
|
4/27/23
|
4/26/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.75
|
0.45
|
0.45
|
0.45
|
0.45
|
EBITDA
1 |
-9.548
|
-18.27
|
-12.56
|
-15.79
|
-20.94
|
EBIT
1 |
-9.647
|
-18.56
|
-12.91
|
-15.97
|
-21.08
|
Operating Margin
|
-1,286.27%
|
-4,124%
|
-2,868%
|
-3,548%
|
-4,684.44%
|
Earnings before Tax (EBT)
1 |
-7.717
|
27.32
|
13.29
|
138.7
|
177.9
|
Net income
1 |
-8.013
|
26.09
|
12.69
|
133.5
|
171.1
|
Net margin
|
-1,068.4%
|
5,797.11%
|
2,819.33%
|
29,672.44%
|
38,027.56%
|
EPS
2 |
-0.9100
|
0.3600
|
0.0985
|
0.8854
|
1.130
|
Free Cash Flow
|
-
|
256.9
|
-11.77
|
-171.7
|
-1,189
|
FCF margin
|
-
|
57,097.47%
|
-2,614.61%
|
-38,151.28%
|
-264,308.22%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
984.93%
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/19/21
|
3/19/21
|
4/19/22
|
4/27/23
|
4/26/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
733
|
2,787
|
4,350
|
4,322
|
4,136
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
257
|
-11.8
|
-172
|
-1,189
|
ROE (net income / shareholders' equity)
|
-
|
0.96%
|
0.29%
|
2.55%
|
3.18%
|
ROA (Net income/ Total Assets)
|
-
|
-0.43%
|
-0.18%
|
-0.19%
|
-0.24%
|
Assets
1 |
-
|
-6,111
|
-6,906
|
-70,166
|
-70,104
|
Book Value Per Share
2 |
59.90
|
39.40
|
34.90
|
35.80
|
36.90
|
Cash Flow per Share
2 |
24.10
|
30.50
|
26.30
|
18.80
|
14.50
|
Capex
1 |
0.1
|
0.58
|
0.43
|
-
|
-
|
Capex / Sales
|
13.2%
|
127.78%
|
95.33%
|
-
|
-
|
Announcement Date
|
3/19/21
|
3/19/21
|
4/19/22
|
4/27/23
|
4/26/24
|
|
1st Jan change
|
Capi.
|
---|
| +2.46% | 5.95M | | +24.53% | 45.07B | | +30.99% | 23.39B | | +24.13% | 16.08B | | +21.15% | 14.6B | | +68.67% | 14.01B | | -0.05% | 6.79B | | -13.29% | 6.38B | | -8.87% | 5.73B | | +13.53% | 5.64B |
Generic Pharmaceuticals
|